Human medicines European public assessment report (EPAR): Votubia, everolimus, Date of authorisation: 02/09/2011, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Maviret, glecaprevir,pibrentasvir, Date of authorisation: 26/07/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Date of authorisation: 19/02/2015, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Atectura Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Enerzair Breezhaler, indacaterol,glycopyrronium bromide,mometasone, Date of authorisation: 03/07/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Status: Authorised

ADHD medicines

Classification of a product as intended for a limited market and eligibility for authorisation under Article 23 of Regulation (EU) 2019/6 (Applications for limited markets)

EMEA-003153-PIP01-21

First-in-class treatment to delay onset of type 1 diabetes